Menopausal hormone therapy after breast cancer
- PMID: 15987471
- PMCID: PMC1175078
- DOI: 10.1186/bcr1272
Menopausal hormone therapy after breast cancer
Abstract
The use of postmenopausal hormone therapy after breast cancer remains controversial. Evidence shows variation by study design, and even among three randomized controlled trials there is substantial heterogeneity of results. Two Swedish trials of comparable size show relative risks of recurrence of 3.3 and 0.82 on comparing women receiving postmenopausal hormone therapy with control women. The extent of use of tamoxifen and concomitant use of progestins in combination with estrogen, although raised as one possible explanation for this heterogeneity, are not supported by evidence from trials of high-dose progestins used after breast cancer. Caution is needed when considering the use of postmenopausal hormone therapy after breast cancer.
Comment on
-
Menopausal hormone therapy after breast cancer: a meta-analysis and critical appraisal of the evidence.Breast Cancer Res. 2005;7(4):R535-40. doi: 10.1186/bcr1035. Epub 2005 May 19. Breast Cancer Res. 2005. PMID: 15987460 Free PMC article.
References
-
- Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA. 2002;288:321–333. doi: 10.1001/jama.288.3.321. - DOI - PubMed
-
- Coates RJ, Clark WS, Eley JW, Greenberg RS, Huguley CM, Jr, Brown RL. Race, nutritional status, and survival from breast cancer. J Natl Cancer Inst. 1990;82:1684–1692. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
